Researchers have discovered that investigational cancer drug, BEZ235, may reduce the severity of influenza infection by altering host-cell metabolism, representing new treatment avenues.
Browsing: Basic > Drug Development
Antivirulence agents represent an attractive alternative to antibiotics. Here, the authors discuss the advantages, and the gaps in antivirulence therapy.
In this clinical trial focus, the authors discuss difficult-to-treat patients with autoimmune hepatitis, and the potential of additional treatment option JKB-122.
Development of protein vaccine to prevent congenital infection is a public health priority, this research investigates the design of a mucosal synthetic pathogen as a vaccine strategy against congenital toxoplasmosis.
In line with Hepatitis Awareness Month, we spoke to Marcus Dorner about his current research into the host–virus interactions in hepatitis B and C infection, their implications for vaccine development and more.
A novel, bioinspired antimicrobial treatment, consisting of iodo-thiocyanate complexes, has demonstrated promising results as a bactericidal compound, according to new research.
The recurring resistance of the malaria parasite to many drugs compels the design of innovative chemical entities in antimalarial research. In light of this, the authors discuss thiaheterocyclic hHDAC6 inhibitors as potentially powerful novel antimalarials.
In this systematic review from Future Microbiology the author assesses data of Phase I–III trials including malaria-naive adults and adults, children and infants from malaria endemic settings in sub-Saharan Africa.